Genitourinary Drugs Market By Indication (Prostate, Ovarian, Bladder, Cervical Cancer, Erectile Dysfunction, UTI, Urinary Incontinence & STD) By Product (Urologicals, Hormonal Therapy Drugs, Gynecological, Anti-infectives) And Segment Forecasts, 2018 - 2024

Report ID: GVR-1-68038-285-3
Number of Pages: 110
Format: Electronic (PDF)

Historical Range: 2013 - 2015
Industry:Healthcare

Market segmentation

Global Genitourinary Drugs Indication Outlook (Revenue, USD Million, 2013 - 2024)
- Prostate Cancer
- Ovarian Cancer
- Bladder Cancer
- Cervical Cancer
- Renal Cancer
- Erectile Dysfunction
- Urinary Tract Infections
- Urinary Incontinence & Overactive Bladder
- Sexually Transmitted Diseases
- Interstitial Cystitis
- Hematuria
- Benign Prostatic Hyperplasia
Global Genitourinary Drugs Product Outlook (Revenue, USD Million, 2013 - 2024)
- Urologicals
- Hormonal Therapy
- Gynecological
- Anti-infectives
- Others
Genitourinary Drugs Regional Outlook (Revenue, USD Million, 2013 - 2024)
- North America
  - The U.S.
    - U.S. Indication Outlook (Revenue, USD Million, 2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - U.S. Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others
  - Canada
    - Canada Indication Outlook (Revenue, USD Million, 2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - Canada Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others
- Europe
  - UK
    - UK Indication Outlook (Revenue, USD Million, 2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - UK Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others
  - Germany
    - 德国表示前景(收入,百万美元,2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - Germany Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others
- Asia Pacific
  - Japan
    - Japan Indication Outlook (Revenue, USD Million, 2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - Japan Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others
  - China
    - China Indication Outlook (Revenue, USD Million, 2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - China Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others
  - India
    - India Indication Outlook (Revenue, USD Million, 2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - India Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others
- Latin America
  - Brazil
    - Brazil Indication Outlook (Revenue, USD Million, 2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - Brazil Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others
  - Mexico
    - Mexico Indication Outlook (Revenue, USD Million, 2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - Mexico Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others
- MEA
  - South Africa
    - South Africa Indication Outlook (Revenue, USD Million, 2013 - 2024)
      - Prostate Cancer
      - Ovarian Cancer
      - Bladder Cancer
      - Cervical Cancer
      - Renal Cancer
      - Erectile Dysfunction
      - Urinary Tract Infections
      - Urinary Incontinence & Overactive Bladder
      - Sexually Transmitted Diseases
      - Interstitial Cystitis
      - Hematuria
      - Benign Prostatic Hyperplasia
    - South Africa Product Outlook (Revenue, USD Million, 2013 - 2024)
      - Urologicals
      - Hormonal Therapy
      - Gynecological
      - Anti-infectives
      - Others

Report Content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
乐鱼体育手机网站入口
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2013 to 2024
Revenue estimates for technology up to 2024
Revenue estimates for type up to 2024
Revenue estimates for application up to 2024
Regional market size and forecast for product up to 2024

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report -free of charge- including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read ourprivacy policy.